NCT05754801 Yunzhi Essence to Improve the Quality of Life of Patients With Advanced Stage of Cancer
| NCT ID | NCT05754801 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Chinese University of Hong Kong |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 172 participants |
| Start Date | 2024-01-05 |
| Primary Completion | 2027-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 172 participants in total. It began in 2024-01-05 with a primary completion date of 2027-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A randomized, double-blinded, placebo-controlled clinical trial using a Chinese Medicine 'Coriolus Versicolor for improving the quality of life of patients with advanced-stage cancer. Subjects will be randomized into a treatment group or placebo group for 6 months.
Eligibility Criteria
Inclusion Criteria: * Diagnosed with advanced cancer according to the definition from American Cancer Society; * According to the experience of the doctor, by using Palliative Prognostic Index (score\>4), integrated with past cases and professional knowledge judged to have life expectancy not less than six months to two years; * Abbreviated mental test (AMT) score of 6 or above; * Voluntarily participate in this clinical trial and sign the informed consent form (acceptance of close relatives signed informed consent on behalf of the patient); * Refer to the national standard for Clinic terminology of traditional Chinese medical diagnosis and treatment-Part 2:Syndromes/patterns, syndrome of "damp heat spleen" and "spleen deficiency with water stop" (Fulfill 2 of the main symptoms and 2 of the secondary symptoms). Exclusion Criteria: * Patients with a history of allergy to traditional Chinese medicine or Yunzhi; * Patients who required nasal feeding or difficulty swallowing; * Patients with comatose/semi-conscious, cognitively impaired with dementia/confusion, physically too ill with extremely poor general condition, or there was a language barrier.
Contact & Investigator
Zhixiu Lin
PRINCIPAL INVESTIGATOR
Hong Kong Institute of Integrative Medicine
Frequently Asked Questions
Who can join the NCT05754801 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 89 Years, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05754801 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT05754801 currently recruiting?
Yes, NCT05754801 is actively recruiting participants. Contact the research team at louislo@cuhk.edu.hk for enrollment information.
Where is the NCT05754801 trial being conducted?
This trial is being conducted at Hong Kong, Hong Kong.
Who is sponsoring the NCT05754801 clinical trial?
NCT05754801 is sponsored by Chinese University of Hong Kong. The principal investigator is Zhixiu Lin at Hong Kong Institute of Integrative Medicine. The trial plans to enroll 172 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.